Glycologix has filed a notice of an exempt offering of securities to raise $1,750,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Glycologix is raising $1,750,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Daniel Deardorf played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Glycologix
Glycologix Inc. is an emerging biotechnology company targeting locally delivered biopolymers for the protection of soft tissues. Multiple unmet medical conditions can be addressed by replenishment of naturally occurring proteoglycans. Our platform discovery engine enables the preparation of synthetic structural mimics of proteoglycans. Despite their high molecular weight, these novel materials are are highly soluble, enabling optimal tissue coverage. Focused indications for the platform include interstitial cystitis, dry eye, post-surgical adhesion prevention, osteoarthritis, spinal disk disease, and wound repair. Glycologix is supported in part by grants from the NIH.
To learn more about Glycologix, visit http://www.glycologix.com/
Contact:
Daniel Deardorf, Chief Executive Officer
617-480-2536
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.